FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care | Sheppard Mullin Richter & Hampton LLP
The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of...
Source: jdsupra.com
